Agile Therapeutics, Inc. (AGRX)
Aug 26, 2024 - AGRX was delisted (reason: acquired by Insud Pharma)
1.510
0.00 (0.00%)
Inactive · Last trade price on Aug 26, 2024
Agile Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Agile Therapeutics.
Price Target: $0.00 (0.00%)
Analyst Consensus: Hold
No price target forecast data available
Analyst Ratings
According to 1 stock analyst, the rating for Agile Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 18, 2024 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +231.13% | Sep 22, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +694.70% | Jun 26, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +694.70% | Jun 7, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $250 → $150 | Strong Buy | Maintains | $250 → $150 | +9,833.77% | Dec 30, 2022 |
Financial Forecast
Revenue This Year
37.58M
from 19.59M
Increased by 91.78%
Revenue Next Year
51.95M
from 37.58M
Increased by 38.26%
EPS This Year
0.80
from -6.71
EPS Next Year
1.12
from 0.80
Increased by 41.03%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 38.7M | 53.5M | 69.6M |
| Avg | 37.6M | 52.0M | 67.6M |
| Low | 36.1M | 49.9M | 65.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 97.4% | 42.3% | 34.0% |
| Avg | 91.8% | 38.3% | 30.2% |
| Low | 84.3% | 32.8% | 25.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.82 | 1.16 | 2.07 |
| Avg | 0.80 | 1.12 | 2.01 |
| Low | 0.76 | 1.08 | 1.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 45.2% | 84.4% |
| Avg | - | 41.0% | 79.1% |
| Low | - | 35.5% | 72.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.